Alopecia and grey hair are associated with COVID‐19 Severity

Ramos, Paulo Müller; Ianhez, Mayra; Miot, Hélio Amante

doi:10.1111/exd.14220

Cited by 34 publications

(37 citation statements)

References 7 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, patients with androgen sensitive phenotypes have been shown to have increased COVID-19 disease burden. The androgen-mediated phenotype androgenetic alopecia (AGA) has been associated with greater COVID-19 disease severity (5)(6)(7). Further, the progression of AGA in hospitalized men showed a direct association with COVID-19 disease severity; men with more advanced AGA were more likely to require intensive care or die (5,8).…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

McCoy¹,

Goren²,

Cadegiani³

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Antiandrogens have demonstrated a protective effect for COVOD-19 patients in observational and interventional studies. The goal of this study was to determine if proxalutamide, an androgen receptor antagonist, could be an effective treatment for men with COVID-19 in an outpatient setting. A randomized, double-blinded, placebo-controlled clinical trial was conducted at two outpatient centers (Brasilia, Brazil). Patients were recruited from October 21 to December 24, 2020 (clinicaltrials.gov number, NCT04446429). Male patients with confirmed COVID-19 but not requiring hospitalization (COVID-19 8-point ordinal scale <3) were administered proxalutamide 200 mg/day or placebo for up to 7 days. The primary endpoint was hospitalization rate at 30 days post-randomization. A total of 268 men were randomized in a 1:1 ratio. 134 patients receiving proxalutamide and 134 receiving placebo were included in the intention-to-treat analysis. The 30-day hospitalization rate was 2.2% in men taking proxalutamide compared to 26% in placebo, P < 0.001. The 30-day hospitalization risk ratio was 0.09; 95% confidence interval (CI) 0.03–0.27. Patients in the proxalutamide arm more frequently reported gastrointestinal adverse events, however, no patient discontinued treatment. In placebo group, 6 patients were lost during follow-up, and 2 patients died from acute respiratory distress syndrome. Here we demonstrate the hospitalization rate in proxalutamide treated men was reduced by 91% compared to usual care.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

McCoy¹,

Goren²,

Cadegiani³

et al. 2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Even though both androgenetic alopecia and gray hair were not induced by COVID-19, they were both found to be risk factors for a more severe course of the infection. [68][69][70] Most hospitalized F I G U R E 6 Excoriations secondary to severe pruritus over left lower extremity of a COVID-positive (confirmed by PCR) young woman. Pruritus started a few days after onset of fever, cough, and myalgias.…”

Section: Androgenetic Alopecia and Gray Hairmentioning

confidence: 99%

“…65 However, the association of androgenetic alopecia and gray hair with a more severe course of COVID-19 infection was surprising, and it paves the way to new possibilities in treatment modalities using anti-androgens. 68,69 The SARS-CoV-2 virus requires a transmembrane protein for infectivity, the transcription of which is regulated by the androgen receptor, which makes it a reasonable therapeutic, and even prophylactic option. 69 Nevertheless, it is to be noted that, despite the multiple skin findings that have been either hypothesized or confirmed related to COVID-19 infection, multiple characteristics of these findings are yet to be defined.…”

Section: Referencementioning

confidence: 99%

Skin disorders associated with the COVID‐19 pandemic: A review

Akl

El-Kehdy

Salloum

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

In December 2019, a new coronavirus has emerged out of China, the SARS‐Cov‐2 virus, causing a disease known as COVID‐19, which steadily has progressed into a pandemic. This coronavirus affects many organs, including the skin, whose manifestations are a consequence of the disease itself, as well as the preventative measures taken to avoid the infection. This paper reviews the cutaneous manifestations which currently have been encountered during this pandemic. A search was conducted on PubMed, and all relevant articles were included. The results show the occurrence of many cutaneous findings, ranging from those related to the infection itself and to various dermatitides related to the use of personal protective equipment (PPE) utilized by healthcare workers while attending to infected patients. Recognizing these findings is important for the accurate diagnosis of those infected with COVID‐19 as well as the prompt treatment of the side effects caused by PPE that might further impair the effectiveness of healthcare workers.

show abstract

“…В то же время пол, возраст, этническая принадлежность, сопутствующие заболевания и их сложные взаимосвязи с COVID-19 требуют проведения многомерного регрессионного анализа, который авторы не предоставляют для подтверждения своего утверждения о том, что помимо андрогенной алопеции, как первоначально предложили C.G. Wambier et al, седые волосы могут представлять собой еще один независимый фактор риска серьезности заболевания [12].…”

Section: андрогенетическая алопеция и Covid-19unclassified

Hair loss due to a new coronavirus infection: treatment approaches

2021

View full text Add to dashboard Cite

Stress has always been one of the triggers of hair loss. The global pandemic of COVID-19 infection has become such a factor for many people. Considering that the pathogenesis of hair loss in this infection has not been sufficiently studied yet, many authors suggest that, as the infection itself and the associated psychoemotional condition and the therapy can cause diffuse thinning of hair and androgenic alopecia. Several studies demonstrate a link between androgens involved in the pathogenesis of COVID-19 and the possible development of androgenic alopecia. Other researchers have observed many cases of telogen hair loss associated with this infection. In our practice, we also encounter diffuse hair thinning, presumably caused by COVID-19. Often, many patients do not consider necessity of consulting with doctor for hair loss. They look for medical help only when self-medication does not give the expected result. After these attempts to independently conduct therapy in some cases patients develop negative attitude towards certain drugs. In such cases, the doctor’s task is to adequately assess the patient’s condition and offer the optimal therapy in each specific case. Often, diffuse hair thinning of a telogen nature, which has arisen against the background of various infections, can be stopped without the help of drugs. The article describes the experience of applying care products with natural and innovative components in the fight against COVID-19-induced alopecia, which can be applied in the practice of a dermatologist.

show abstract

Alopecia and grey hair are associated with COVID‐19 Severity

Cited by 34 publications

References 7 publications

RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

Skin disorders associated with the COVID‐19 pandemic: A review

Hair loss due to a new coronavirus infection: treatment approaches

Contact Info

Product

Resources

About